白芍总苷对MRL/lpr小鼠狼疮性肾炎的影响

摘要

目的 观察白芍总苷(TGP)对MRL/Ipr小鼠狼疮性肾炎的影响.方法 将MRL/lpr狼疮肾炎小鼠随机分为模型组和TGP组.考马斯亮蓝法检测尿蛋白含量,酶联免疫吸附法(ELISA)检测血清IgG型抗dsDNA抗体、ANA水平,HE染色光镜下观察肾组织病理改变,称脾脏和胸腺湿重,并计算脾脏和胸腺指数.结果 ①与模型组相比,TGP组用药后15、30 d尿蛋白含量显著下降(P＜0.05),用药后30 d抗dsDNA抗体、ANA水平和脾脏质量及其指数均显著下降(P＜0.05),肾脏组织病理损害明显减轻.②TGP组用药后15、30 d与用药前相比,尿蛋白含量、抗dsDNA抗体水平、ANA水平显著下降(P＜0.05),而模型组抗dsDNA抗体水平显著上升(P＜0.05),尿蛋白含量、ANA水平无显著差异;TGP组用药后30d与用药后15d相比尿蛋白含量显著下降(P＜0.05),抗体水平无显著差异.结论 白芍总苷可以降低尿蛋白含量和血清抗dsDNA抗体、ANA水平,明显改善肾组织病理损害,对MRL/lpr小鼠狼疮性肾炎具有一定疗效.%Objective To observe the therapeutic effect of total glucosides of paeony (TGP) on lupus nephritis (LN) in MRL/lpr mice. Methods MRL/lpr mice with lupus nephritis were randomized into model group and TGP group. The urinary protein content was detected using Coomassie brilliant blue, and the serum levels of IgG anti-double-stranded DNA (dsDNA) antibodies and antinuclear antibodies (ANA) were measured by enzyme-linked immunosorbent assay (ELISA). The changes in the renal pathology were examined microscopically, and the spleen and thymus were weighed to calculate the spleen and thymus indexes. Results At 15 and 30 days after TGP administration, the urinary protein content in the TGP group was significantly lower than that in the model group (PO.05). TGP treatment significantly lowered the serum levels of anti-dsDNA antibodies and ANA and the weight and index of spleen (P< 0.05), resulting also in lessened renal pathology at 30 days after the administration. Compared to those before TGP treatment, the urinary protein content and the levels of anti-dsDNA antibodies and ANA decreased significantly at 15 and 30 days after TGP administration (PO.05), while in the model group, the level of anti-dsDNA increased significantly without obvious changes in urinary protein content or ANA. At 30 days after TGP administration, the urinary protein content was significantly lowered in the TGP group as compared to that at 15 days (P<0.05), but the antibodies showed no significant changes. Conclusion TGP can reduce urinary protein content and serum levels of anti-dsDNA antibodies and ANA, and lessen renal pathology in MRL/lpr mice with lupus nephritis, suggesting its therapeutic effect on lupus nephritis.